Lanreotide Autogel Therapy in Patients with Acromegaly 2008;68:473–80.


24. Berg C, Petersenn S, Lahner H, et al., Cardiovascular risk factors in patients with uncontrolled and long-term avromegaly: comparison with mateched data from the gebneral population and the effect of disease control, J Clin Endocr Metab, 2010;95:3648–56.


25. Mazziotti G, Floriani I, Bonadonna S, et al., Effects of somatostatin analogues on glucose homeostasis: A metaanalysis of acromegaly studies, J Clin Endocrinol Metab, 2009;94:1500–8.


26. Giusti M, Cicarelli E, Dallabonzana D, et al., Clinical results of long term slow-release treatment of acromegaly, Eur J Clin Invest, 1997;27:277–84.


27. Barkan AL, Burman P, Clemmons DR, et al., Glucose homeostasis and safety in patents with acromegaly converted from long-acting octreotide to pegvisomant, J Clin Endocinol Metab, 2005;90:5684–91.


28. Cozzi R, Dallabonzana D, Attanasio R, et al., A comparison between octreotide – LAR and lanreotide – SR in the chronic treatment of acromegaly, Eur J Endocrinol, 1999;141:267–71.


29. Baldelli R, Battista C, Leonetti F, et al., Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment, Clin Endocrinol (Oxf), 2003;59:492–9.


30. Colao A, Ferone D, Marzullo P, et al., Systemic complications of acromegaly: epidemiology, pathogenesis, and management, Endocr Rev, 2004;25:102–52.


31. Hradec J, Král J, Janota J, et al., Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog), Am J Cardiol, 1999;83:1506–9.


32. Maison P, Tropeano A-I, Macquin-Mavier I, et al., Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis, J Clin Endocrinol Metab, 2007;92:1743–7.


33. Mazzioti G, Giustina A, Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review, Pituitary, 2010;13:60–7.


34. Maiza JC, Vezzosi D, Matta M, et al., Long-term (up to 18 years) effects on GH/IGF I hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa, Clin Endocrinol (Oxf), 2007;67:282–9.


35. Attanasio R, Lanzi R, Losa M, et al., Effects of lanreotide Autogel on growth hormone, insulin like growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study, Endocr Pract, 2008;14:846–55.


36. Colao A, Auriemma RS, Rebora A, et al., Significant tumour shrinkage after 12 months of lanreotide Autogel- 120mg treatment given first-line in acromegaly, Clin Endocrinol (Oxf), 2009;71:237–45.


37. Zatelli MC, Piccin D, Ambrosio MR, et al., Antiproliferative effects of somatostatin analogs in pituitary adenomas, Pituitary, 2006;9:27–34.


38. Auriemma RS, Galdiero M, Grasso LF, et al., Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal, Eur J Endocrinol, 2010;162:993–9.


39. Landolt AM, Haller D, Lomax N, et al., Octreotide may act as a radioprotective agent in acromegaly, J Clin Endocrinol Metab, 2000;85:1287–9.


40. Ning S, Knox SJ, Harsh GR, et al., Lanreotide promotes apoptosis and is not radioprotective in GH3 cells, Endocr Relat Cancer, 2009;16:1045–55.


41. Alexopoulou O, Abrams P, Verhelst J, et al., Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR, Eur J Endocrinol, 2004;151:317–24.


42. Bronstein M, Musolino N, Jallad R, et al., Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days, Clin Endocrinol (Oxf), 2005;63:514–9.


43. Salvatori R, Nachtigall LB, Cook DM, et al., Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly, Pituitary, 2010;13:115–22. 44. Bevan JS, Newell-Price J, Wass JA, et al., Home


administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective, Clin Endocrinol (Oxf), 2008;68:343–9.


45. Colao A, Ferone D, Marzullo P, et al., Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly, J Clin Endocrinol Metab, 2001;86:2779–86.


46. Abrams P, Alexopoulou O, Abs R, et al., Optimalization and cost management of lanreotide-Autogel therapy in acromegaly, Eur J Endocrinol, 2007;157:571–7.


47. Antonijoan RM, Barbanoj MJ, Cordero JA, et al., Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers, J Pharm Pharmacol, 2004;56:471–6.


48. Trocóniz IF, Cendrós J-M, Peraire C, et al., Population Pharmacokinetic analysis of lanreotide Autogel in healthy subjects: Evidence for injection interval of up to 2 months, Clin Pharmacokinet, 2009;48:51–62.


49. Wuster C, Both S, Cordes U, at al., Primary treatment of acromegaly with high-dose lanreotide: a case series, J Med Case Reports, 2010;4:85.


50. Ronchi CL, Rizzo E, Lania AG, et al., Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal, Eur J Endocrinol, 2008;158:19–25.


51. Jezková J, Marek J, Hána V, et al., Gamma knife radiosurgery for acromegaly – long-term experience, Clin Endocrinol, 2006;64:588–95.


52. Vladyka V, Licák R, Novotný J, et al., Radiation tolerance of functioning pituitary tissue in gamma knife surgery for pituitary adenomas, Neurosurgery, 2003;52:309–16.


53. Marek J, Jezková J, Hána V, et al., Is it possible to avoid hypopituitarism after the irradiation of pituitary adenomas by the Leksell gamma-knife? 11th European Congress of Endocrinology, Istanbul, Turkey, 25–29 April 2009, Endocrine Abstracts 2009;20:574. Available at: www.endocrine-abstracts.org/ea/0020/ea0020p574.htm (Accessed 20 August 2010.)


54. Cozzi R, Attanasio R, Lodrini S, et al., Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status, Clin Endocrinol (Oxf), 2004;61:209–15.


55. Marzullo P, Ferone D, Di Somma C, et al., Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients, Pituitary, 1999;1:115–20.


56. Selvarajah D, Webster J, Ross R, et al., Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly, Eur J Endocrinol, 2005;152:569–74.


57. Jezková J, Marek J, Diagnosis and treatment of prolactinomas, Expert Rev Endocrinol Metab, 2009;4:135–42.


58. Brue T, ACROSTUDY: Status update on 469 patients, Horm Res, 2009;71(Suppl. 1):34–8.


59. Feenstra J, de Herder WW, ten Have SM, et al., Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly, Lancet, 2005;365:1644–6.


60. Neggers SJ, van Aken MO, Janssen JA et al, Long-term efficacy and safetyx of combined treatment of somatostatin analogs and pegvisomant in acromegaly, J Clin Endocrinol Metab, 2007;92:4598–601.


61. Neggers SJ, de Herder WW, Janssen JA, et al., Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients, Eur J Endocrinol, 2009;160:529–33.


62. Van der Lely AJ, Bernabeu I, Cap J, et al., Efficacy and safety of co-administration of lanreotide Autogel 120mg monthly with weekly pegvisomant in patients with acromegaly partially controlled by somatostatin analogs, Abstract P3-276. The 92nd Endocrine Society Annual Meeting, San Diego, Ca, June 19–22, 2010, Endocrine Abstracts 2010;22:625. Available at: www.endocrine-abstracts.org/ ea/0022/ea0022p625.htm (accessed 20 August 2010.)


63. Biering H, Saller B, Bauditz J, et al., Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance


experience and a report of a patient with histologically proven chronic mild active hepatitis, Eur J Endocrinol, 2006;154:213–20.


64. Neggers SJ, van Aken MO, de Herder WW, et al., Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant, J Clin Endocrinol Metab, 2008;93:3853–9.


65. Melmed S, Colao A, Barkan M, et al., Guidelines for acromegaly management: an update, J Clin Endocrinol Metab, 2009;94:1509–17.


66. Karavitaki N, Turner HE, Adams CBT, et al., Surgical debulking of pituiary macroadenomas causing acromegaly improves control by lanreotide, Clin Endcorinol, 2008;68:970–5.


67. Carlsen SM, Lund-Johansen M, Schreiner T, et al., Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial, J Clin Endocrinol Metab, 2008;93:2984–90.


68. Mao ZG, Zhu YH, Tang HL, et al., Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomized trial, Eur J Endocrinol, 2010;162:661–6.


69. Bolanowski M, Bar-Andziak E, Kos-Kudla B, et al., Consensus statement of the Polish Society for Endocrinology: presurgical somatostatin analogs in acromegaly, Neuro Endocrinol Lett, 2008;29:59–62.


70. Taboada GF, Luque RM, Bastos W, et al., Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and non- functioning pituitary adenomas, Eur J Endocrinol, 2007;156:65–74.


71. Durán-Prado M, Saveanu A, Luque RM, et al., A potential role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs, J Clin Endcorinol Metab, 2010;95:2497–502.


72. Bruns C, Lewis I, Briner U, et al., SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile, Eur J Endocrnol, 2002;146: 707–16.


73. Waser B, Cescato R, Tamma ML, et al., Absence of somatostatin SST2 receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model, Eur J Pharmacol, 2010;644(1-3):257–262.


74. Pöll F, Lehmann D, Illing S, et al., Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation, Mol Endocrinol, 2010;24:436–46.


75. Perterssen S, Schopohl J, Barkan A, et al., Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial, J Clin Endocrinol Metab, 2010;95:2781–9.


76. Stefaneanu L, Kovacs K, Horvath E, et al., Dopamine D2 receptor gene expression in human adenohypophysial adenomas, Endocrine, 2001;14(3):329–36.


77. Ferone D, Saveanu A, Culler MD, et al., Novel chimeric somatostatin analogs: facts and perspectives, Eur J Endocrinol, 2007;156(Suppl 1):S23–8.


78. Saveanu A, Jaquet P, Brue T, et al., Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas, Mol Cell Endocrinol, 2008;286(1-2):206–13.


79. Colao A, Filippella M, Pivonello R, et al., Combined therapy with somatostatin analogues and dopamine agonists in the treatment of pituitry tumours, Eur J Endocrinol, 2007;156:S57-S63.


80. Ferone D, Gatto F, Arvigo M, et al., The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology, J Mol Endocrinol, 2009;42:361–70.


81. Jaquet P, Gunz G, Saveanu A, et al., BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptor ligands in GH-secreting pituitary adenomas partial responders to octreotide, J Endocrinol Invest, 2005;28(11 Suppl. International):21–7.


EUROPEAN ENDOCRINOLOGY


41


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68